Bristol Myers defends pipeline, reinforces later stage BD interest
Bristol Myers Squibb is re-emphasizing its plan to stave off one of the industry’s most daunting patent cliffs. Speaking to analysts on its earnings call on Thursday, executives at the New Jersey pharma company touted ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.